

Melpomeni Fani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6849772/publications.pdf>

Version: 2024-02-01

41
papers

3,075
citations

186265

28
h-index

276875

41
g-index

42
all docs

42
docs citations

42
times ranked

2531
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals. <i>Cancers</i> , 2022, 14, 1172.	3.7	27
2	Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 581-594.	5.7	29
3	SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers. <i>Pharmaceuticals</i> , 2021, 14, 300.	3.8	5
4	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021, 146, 56-73.	2.8	120
5	Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside. <i>Chimia</i> , 2021, 75, 500.	0.6	4
6	Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?. <i>Journal of Nuclear Medicine</i> , 2021, 62, 44S-50S.	5.0	8
7	Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates. <i>Pharmaceuticals</i> , 2021, 14, 19.	3.8	8
8	Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [¹⁷⁷ Lu]Lu-OPS201 Compared to the Agonist [¹⁷⁷ Lu]Lu-DOTA-TATE. <i>Pharmaceuticals</i> , 2021, 14, 1265.	3.8	10
9	Evaluation of a New ¹⁷⁷ Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5. <i>Molecules</i> , 2020, 25, 4155.	3.8	2
10	High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes. <i>Frontiers in Oncology</i> , 2020, 10, 979.	2.8	50
11	A new ⁶⁸ Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting. <i>EJNMMI Research</i> , 2020, 10, 90.	2.5	3
12	Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog ¹⁷⁷ Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?. <i>Journal of Nuclear Medicine</i> , 2019, 60, 393-399.	5.0	42
13	⁶⁸ Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5843-5852.	3.6	36
14	Design and development of the theranostic pair ¹⁷⁷ Lu-OPS201/ ⁶⁸ Ga-OPS202 for targeting somatostatin receptor expressing tumors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 635-645.	1.0	20
15	In Vivo Biokinetics of ¹⁷⁷ Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-7.	0.8	11
16	New Developments in Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 167-171.	5.0	41
17	Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists. <i>Journal of Nuclear Medicine</i> , 2018, 59, 547-548.	5.0	6
18	Safety, Biodistribution, and Radiation Dosimetry of ⁶⁸ Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 909-914.	5.0	65

#	ARTICLE	IF	CITATIONS
19	Sensitivity Comparison of ⁶⁸ Ga-OPS202 and ⁶⁸ Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 915-921.	5.0	121
20	The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist. <i>EJNMMI Research</i> , 2018, 8, 75.	2.5	15
21	Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2318-2327.	6.4	82
22	The somatostatin receptor 2 antagonist ⁶⁴ Cu-NODAGA-JR11 outperforms ⁶⁴ Cu-DOTA-TATE in a mouse xenograft model. <i>PLoS ONE</i> , 2018, 13, e0195802.	2.5	36
23	Biodistribution, Pharmacokinetics, and Dosimetry of ¹⁷⁷ Lu-, ⁹⁰ Y-, and ¹¹¹ In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist ¹⁷⁷ Lu-DOTATATE: The Mass Effect. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1435-1441.	5.0	100
24	Somatostatin Receptor Antagonists for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 61S-66S.	5.0	188
25	Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms. <i>Pharmaceuticals</i> , 2017, 10, 30.	3.8	44
26	Localization of Hidden Insulinomas with ⁶⁸ Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1075-1078.	5.0	104
27	Preoperative localization of adult nesidioblastosis using ⁶⁸ Ga-DOTA-exendin-4-PET/CT. <i>Endocrine</i> , 2015, 50, 821-823.	2.3	34
28	Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1248-1252.	5.0	197
29	Unexpected Sensitivity of sst ₂ Antagonists to N-Terminal Radiometal Modifications. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1481-1489.	5.0	129
30	In Vivo Imaging of Folate Receptor Positive Tumor Xenografts Using Novel ⁶⁸ Ga-NODAGA-Folate Conjugates. <i>Molecular Pharmaceutics</i> , 2012, 9, 1136-1145.	4.6	45
31	Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1876-1885.	6.4	43
32	Radiopharmaceutical development of radiolabelled peptides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 11-30.	6.4	182
33	Radiopeptide Imaging and Therapy in Europe. <i>Journal of Nuclear Medicine</i> , 2011, 52, 42S-55S.	5.0	181
34	Development of new folate-based PET radiotracers: preclinical evaluation of ⁶⁸ Ga-DOTA-folate conjugates. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 108-119.	6.4	39
35	[⁶⁸ Ga]NODAGA-RGD for imaging $\alpha_3\beta_1$ integrin expression. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1303-1312.	6.4	111
36	First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1412-1417.	5.0	157

#	ARTICLE	IF	CITATIONS
37	Novel ⁶⁴ Cu- and ⁶⁸ Ga-Labeled RGD Conjugates Show Improved PET Imaging of $\alpha_5\beta_1$ Integrin Expression and Facile Radiosynthesis. Journal of Nuclear Medicine, 2011, 52, 1276-1284.	5.0	141
38	Evaluation of ¹⁷⁷ Lu-DOTA-sst ₂ Antagonist Versus ¹⁷⁷ Lu-DOTA-sst ₂ Agonist Binding in Human Cancers In Vitro. Journal of Nuclear Medicine, 2011, 52, 1886-1890.	5.0	96
39	PET of Somatostatin Receptor-Positive Tumors Using ⁶⁴ Cu- and ⁶⁸ Ga-Somatostatin Antagonists: The Chelate Makes the Difference. Journal of Nuclear Medicine, 2011, 52, 1110-1118.	5.0	218
40	Radiolabeled Bicyclic Somatostatin-Based Analogs: A Novel Class of Potential Radiotracers for SPECT/PET of Neuroendocrine Tumors. Journal of Nuclear Medicine, 2010, 51, 1771-1779.	5.0	36
41	⁶⁸ Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media and Molecular Imaging, 2008, 3, 53-63.	0.8	288